High-Cost Cancer Treatment Across Borders in Conflict Zones: Experience of Iraqi Patients in Lebanon.
Journal
JCO global oncology
ISSN: 2687-8941
Titre abrégé: JCO Glob Oncol
Pays: United States
ID NLM: 101760170
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
entrez:
8
2
2020
pubmed:
8
2
2020
medline:
29
7
2021
Statut:
ppublish
Résumé
Conflict-induced cross-border travel for medical treatment is commonly observed in the Middle East. There has been little research conducted on the financial impact this has on patients with cancer or on how cancer centers can adapt their services to meet the needs of this population. This study examines the experience of Iraqi patients seeking care in Lebanon, aiming to understand the social and financial contexts of conflict-related cross-border travel for cancer diagnosis and treatment. After institutional review board approval, 60 Iraqi patients and caregivers seeking cancer care at a major tertiary referral center in Lebanon were interviewed. Fifty-four respondents (90%) reported high levels of financial distress. Patients relied on the sale of possessions (48%), the sale of homes (30%), and vast networks to raise funds for treatment. Thematic analysis revealed several key drivers for undergoing cross-border treatment, including the conflict-driven exodus of Iraqi oncology specialists; the destruction of hospitals or road blockages; referrals by Iraqi physicians to Lebanese hospitals; the geographic proximity of Lebanon; and the lack of diagnostic equipment, radiotherapy machines, and reliable provision of chemotherapy in Iraqi hospitals. As a phenomenon distinct from medical tourism, conflict-related deficiencies in health care at home force patients with limited financial resources to undergo cancer treatment in neighboring countries. We highlight the importance of shared decision making and consider the unique socioeconomic status of this population of patients when planning treatment.
Identifiants
pubmed: 32031440
doi: 10.1200/JGO.19.00281
pmc: PMC6998032
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
59-66Références
Am Soc Clin Oncol Educ Book. 2017;37:35-39
pubmed: 28561659
Soc Sci Med. 2008 Jul;67(1):101-10
pubmed: 18468756
Ann Oncol. 2019 Jul 1;30(7):1061-1070
pubmed: 31046080
N Engl J Med. 2013 Oct 17;369(16):1484-6
pubmed: 24131175
Med Anthropol. 2010 Oct;29(4):344-62
pubmed: 21082482
Oncologist. 2013;18(4):381-90
pubmed: 23442307
Fertil Steril. 2009 Sep;92(3):904-6
pubmed: 19249025
Soc Sci Med. 2009 Jul;69(2):172-7
pubmed: 19501443
J Cancer. 2014 Jun 03;5(6):491-8
pubmed: 24959302
Lancet Oncol. 2018 Mar;19(3):291-292
pubmed: 29508747
J Pediatr Hematol Oncol. 2012 Mar;34 Suppl 1:S19-20
pubmed: 22357145
Asia Pac Viewp. 2011;52(3):260-71
pubmed: 22216475
Glob Public Health. 2018 Mar;13(3):288-297
pubmed: 29099332
BMJ. 1999 Jan 16;318(7177):203
pubmed: 9888945
J Glob Oncol. 2018 Sep;4:1-4
pubmed: 30241196
Lancet. 2014 Feb 1;383(9915):449-57
pubmed: 24452046
Cancer. 2014 Oct 15;120(20):3245-53
pubmed: 24954526